CYP2A6 genetic variation and dexmedetomidine disposition

European Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2012, Pages 937-942

  Kohli, Utkarsh ^a   Pandharipande, Pratik ^b   Muszkat, Mordechai ^a   Sofowora, Gbenga G ^a   Friedman, Eitan A ^a   Scheinin, Mika ^c   Wood, Alastair J J ^d,e   Ely, E Wesley ^b,f   Tyndale, Rachel F ^g   Choi, Leena ^b   Stein, C Michael ^a   Kurnik, Daniel ^a,h  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF TURKU   (Finland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Symphony Capital   (United States)

^f GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bayesian modeling; CYP2A6; Dexmedetomidine; Pharmacogenetics

Indexed keywords

DEXMEDETOMIDINE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYP2A6 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG METABOLISM; ETHNICITY; EVENING DOSAGE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTENSIVE CARE UNIT; MALE; MORNING DOSAGE; PHARMACOGENETICS; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BAYES THEOREM; DEXMEDETOMIDINE; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS; MALE; MIDDLE AGED;

EID: 84864198770     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1208-z     Document Type: Article

References (33)

1. Gerlach AT, Dasta JF (2007) Dexmedetomidine: an updated review. Ann Pharmacother 41(2):245-252
2. Talke P, Richardson CA, Scheinin M, Fisher DM (1997) Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg 85(5):1136-1142 (Pubitemid 27471539)
3. Vilo S, Rautiainen P, Kaisti K, Aantaa R, Scheinin M, Manner T, Olkkola KT (2008) Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth 100(5):697-700 (Pubitemid 351774374)
4. Klotz U (2007) The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 46(4):271-279 (Pubitemid 46507006)
5. Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC (2008) Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 66(6):826-837
6. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358(10):999-1008 (Pubitemid 351347099)
7. Abbott Laboratories (2008) Precedex® product label. Abbott Laboratories, Abbott Park, IL
8. Perez-Stable EJ, Herrera B, Jacob P III, Benowitz NL (1998) Nicotine metabolism and intake in black and white smokers. JAMA 280(2):152-156 (Pubitemid 28498387)
9. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, Sharp DJ, Eriksen MP, Pirkle JL, Maurer KR (1998) Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 280(2):135-139 (Pubitemid 28498384)
10. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80(3):282-297 (Pubitemid 44313906)
11. Benowitz NL, Swan GE, Jacob P III, Lessov-Schlaggar CN, Tyndale RF (2006) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80(5):457-467 (Pubitemid 44767882)
12. Malaiyandi V, Sellers EM, Tyndale RF (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77(3):145-158 (Pubitemid 40269130)
13. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA, Dittus RS, Bernard GR, Ely EW (2007) Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 298(22):2644-2653 (Pubitemid 350254956)
14. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG (2009) Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 301(5):489-499
15. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK (2002) The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 166(10):1338-1344 (Pubitemid 35292699)
16. *10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 15(3):189-192 (Pubitemid 40569906)
17. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Phar-macogenetics 14(9):615-626 (Pubitemid 39281816)
18. Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF, Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76 (1):64-72 (Pubitemid 38844735)
19. Mwenifumbo JC, Al KN, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 29(5):679-688 (Pubitemid 351614592)
20. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11(4):400-409
21. Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29(5):1322-1329 (Pubitemid 20053858)
22. Nunoya K, YokoiT, Takahashi Y, Kimura K, Kinoshita M, Kamataki T (1999) Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem 126 (2):402-407 (Pubitemid 29408211)
23. *9). Pharmacogenetics 13(11):689-695 (Pubitemid 38324583)
24. *17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76(6):519-527 (Pubitemid 39601542)
25. Ji QC, Zhou JY, Gonzales RJ, Gage EM, El Shourbagy TA (2004) Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection. Rapid Commun Mass Spectrom 18(15):1753-1760 (Pubitemid 39024923)
26. Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, Hakala K, Scheinin H, Knuuti J, Scheinin M (2006) Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 105(5):902-910 (Pubitemid 44655500)
27. Beal S, Sheiner L, Boeckmann A (eds) (1989) NONMEM users guides. ICON Development Solutions, Ellicott City, MD
28. Choi L, Caffo BS, Kohli U, Pandharipande P, Kurnik D, Ely EW, Stein CM (2011) A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. J Pharmacokinet Pharmacodyn 38(5):613-636
29. Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
30. Lunn DJ, Wakefield J, Thomas A, Best N, Spiegelhalter D (1999) PKBugs user guide. Dept. Epidemiology & Public Health, Imperial College School of Medicine, London
31. Spiegelhalter D, Thomas A, Best N, Lunn D (2003) Win BUGS user manual, version 1.4. MRC Biostatistics Unit, Institute of Public Health and Department of Epidemiology and Public Health, Imperial College School of Medicine, London
32. Lacy CF, Armstrong LL, Goldman MP, Lance LL (eds) (2007) Cytochrome P450 enzymes: substrates, inhibitors, and inducers. In: Drug information handbook, 15th ed. LexiComp, Hudson, OH, pp 1899-1912
33. Venn RM, Karol MD, Grounds RM (2002) Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 88(5):669-675 (Pubitemid 34498595)